Paranasal Sinus Teratocarcinosarcoma with Intradural Extension

Wellman, Mark; Kerr, Paul; Battistuzzi, Susan; Cristante, Loris

doi:10.2310/7070.2002.10895

Cited by 16 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in 25 of 48 (52%) patients reported until now, epistaxis was a leading clinical symptom [1,5,6,9,[11][12][13][14][15][16][17][18][19][20][21]. All patients suffering from SNTC are adults with a male preponderance (M:F-ratio ≈ 6:1) and with no evidence of a particular racial predisposition [3,10].…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Rationale for Individualized Therapy in Sinonasal Teratocarcinosarcoma (SNTC): Case Report

Nitsche

Hermann²,

Christiansen³

et al. 2005

Oncol Res Treat

View full text Add to dashboard Cite

Background: Sinonasal Teratocarcinosarcoma (SNTC) is a very unusual and aggressive neoplasm characterized by the combination of malignant teratoma and carcinosarcoma features. We present the first case of malignant SNTC treated with individualized multimodal therapy including a histology-specific chemotherapy. Case Report: A 31-year-old man presented with an obstruction of the right pansinus. Histology showed an SNTC with major parts of small cell, poorly differentiated carcinoma and a small proportion of highly differentiated embryonal rhabdomyosarcoma. An operation was performed followed by intraoperative application of a 5-FU ointment. Adjuvant chemotherapy with cisplatin, etoposid and ifosfamid were given in regard to the major components of this heterogeneous tumor. Radiotherapy up to 59.4 Gy was applied. Conclusion: 36 months after the end of therapy, there is no sign of tumor recurrence or metastasis in our patient. We suggest that surgery, radiotherapy and a histology-specific multidrug chemotherapy seems to be a therapeutic approach that is appropriate for this heterogeneous tumor.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Therefore surgery and radiotherapy with or without chemotherapy seem to be most effective for this disease. The doses prescribed for radiotherapy treatment in the literature varied from 45 to 70 Gy [1,15,16,18,21,23,26]. Facing the fact that the SNTC is a very rare malignant disease, adequate treatment remains still unclear.…”

Section: Discussionmentioning

confidence: 99%

Rationale for Individualized Therapy in Sinonasal Teratocarcinosarcoma (SNTC): Case Report

Nitsche

Hermann²,

Christiansen³

et al. 2005

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Factors affecting prognosis are multifactorial and include age, gender and ethnicity as well as tumour location, histological type, grade and stage 17. Should the tumour recur, it is most likely to do so locally and at an early stage in follow-up 23–25…”

Section: Discussionmentioning

confidence: 99%

Very unusual case of a primary sinonasal germ cell tumour

et al. 2020

View full text Add to dashboard Cite

Sinonasal malignancies are a very rare diagnosis. We present a unique case of a 32-year-old man who presented with symptoms of worsening sinusitis and periorbital cellulitis. Investigation found a sinonasal malignancy and pathology confirmed this to be a primary germ cell tumour. The patient was managed with chemotherapy, surgery and consolidation radiotherapy and has remained well to date. This case report outlines an unusual presentation and diagnostic challenge for the primary care physician, ear, nose and throat surgeon, pathologist and oncologist with review of the surrounding literature.

show abstract

“…Neurosurgeons rarely encounter this neoplasm because of the usual location in the nasopharyngeal tract. The most common presenting symptoms are nasal airway obstruction and epistaxis 2,3,5,6,9 and to a lesser extent dysphagia and odynophagia. 7 Neurological symptoms are rare with SNTCS as they do not usually invade the intracranial space.…”

Section: Discussionmentioning

confidence: 99%

Intracerebral Metastasis of a Sinonasal Teratocarcinosarcoma: A Case Report

et al. 2010

View full text Add to dashboard Cite

Sinonasal teratocarcinosarcoma (SNTCS) is a rare, malignant neoplasm that contains both mesenchymal and epithelial components. The mortality rate for this tumor is $60% within 3 years, with the average survival rate being 1.7 years. Usually, this neoplasm presents with symptoms of nasal obstruction and epistaxis. Neurological symptoms from intracranial extension and dural invasion are rare presentations for this neoplasm. We present the first known case of an intracerebral metastasis of a previously resected SNTCS.

show abstract

Paranasal Sinus Teratocarcinosarcoma with Intradural Extension

Cited by 16 publications

References 0 publications

Rationale for Individualized Therapy in Sinonasal Teratocarcinosarcoma (SNTC): Case Report

Rationale for Individualized Therapy in Sinonasal Teratocarcinosarcoma (SNTC): Case Report

Very unusual case of a primary sinonasal germ cell tumour

Intracerebral Metastasis of a Sinonasal Teratocarcinosarcoma: A Case Report

Contact Info

Product

Resources

About